Impact of the COVID‐19 pandemic on outcomes of cholecystectomy for acute cholecystitis: a national cohort study

Abstract

BackgroundThe COVID‐19 pandemic was associated with significant disruptions to healthcare provision globally and in Aotearoa New Zealand. It remains unclear how this disruption affected the surgical management of acute cholecystitis and whether there are ongoing impacts.MethodsWe conducted a secondary analysis of two multicentre cohort studies (CHOLECOVID and CHOLENZ) on patients who underwent cholecystectomy for acute cholecystitis. Participants were categorized into pre‐pandemic (September–November 2019), pandemic (March–May 2020), and late‐pandemic (August–October 2021) phases. Baseline demographics, clinical management, and 30‐day postoperative complications were assessed between phases. Multivariable logistic regression was used to explore the impact of timing of operation on rates of hospital readmission and postoperative complications.Results517 participants were included, of whom 85 (16%) were in the pre‐pandemic‐phase, 52 (10%) were in the pandemic phase, and 380 (73%) were in the late‐pandemic phase. Pandemic and late‐pandemic phase participants were more comorbid and had higher rates of obesity and deranged blood results than pre‐pandemic. After multivariable adjustment, there were no differences in rates of hospital readmission or postoperative complications at 30‐day follow‐up across phases.ConclusionThe COVID‐19 pandemic had minimal impacts on the provision of cholecystectomy for acute cholecystitis in Aotearoa New Zealand. However, patients managed during the COVID‐19 pandemic were more comorbid and had higher rates of obesity and elevated inflammatory markers.